Knight et al – Supplementary Table
Supplemental Table 1:
Cell lineDensitometry
AROS SIRT1
ARPE19 65.8 10.7
WI38 0.1 31.9
MCF10A 16.7 51.9
HCT116 115.3 177.6
HCT116 p53-/- 89.5 189.9
MCF7 15.6 127.2
R2 value 0.394
**
Mock AROS 20.0
0.5
1.0
1.5
2.0
2.5
3.0
Knight et al – Supplementary Figure 1
AROS 2 siRNAMock
Fold
apo
ptos
is in
duct
ion
0
1
2
3
4
5Fo
ld a
popt
osis
indu
ctio
n
SIRT1 siRNA
AROS 1 siRNA
+
+ +
+--
- -
A Bn.s.
n.s.
Mock SIRT1 AROS 10
20
40
60
80
100
120
Knight et al – Supplementary Figure 2
mR
NA
exp
ress
ion
(%)
siRNA
HCT116 m
RN
A e
xpre
ssio
n (%
)
siRNA
HCT116 p53-/-
mR
NA
exp
ress
ion
(%)
siRNA
MCF7
mR
NA
exp
ress
ion
(%)
siRNA
WI-38
mR
NA
exp
ress
ion
(%)
siRNA
MCF10A
Mock SIRT1 AROS 10
20
40
60
80
100
120
140
Mock SIRT1 AROS 10
20
40
60
80
100
120
140
Mock SIRT1 AROS 10
20
40
60
80
100
120
140
Mock SIRT1 AROS 10
20
40
60
80
100
120
140
Lam
in A
C m
RN
ASI
RT1
mR
NA
ARO
S m
RN
A
Lam
in A
C m
RN
ASI
RT1
mR
NA
ARO
S m
RN
A
Lam
in A
C m
RN
ASI
RT1
mR
NA
ARO
S m
RN
A
Lam
in A
C m
RN
ASI
RT1
mR
NA
ARO
S m
RN
A
Lam
in A
C m
RN
ASI
RT1
mR
NA
ARO
S m
RN
A
0
1
2
3
4
5
6
Moc
k
Moc
k
SIRT
1
AR
OS
siRNA
Fold
apo
ptos
is v
s. M
ock
******
Etoposide and TSA
0
2
4
6
8
10
***
***M
ock
Moc
k
AR
OS
SIRT
1
UV-C irradiation
Knight et al – Supplementary Figure 3
Condition
β-actin
K382Ac
Treatment
p53Et
opos
ide
and
TSA
UV-
C
Con
trol
Con
trol
*
37kDa
50kDa
50kDa
A
B
